查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611039

抗血管内皮生长因子治疗市场规模、份额、趋势分析报告：按产品、疾病、地区、细分市场预测，2025-2030

Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

抗血管内皮生长因子治疗市场成长与趋势

根据Grand View Research, Inc.最新报告，预计到2030年，全球抗血管内皮生长因子治疗市场规模将达到129亿美元，预测期内复合年增长率为-2.35%。增加抗 VEGF 治疗研究和开发资金以加速开发新药预计将加速市场成长。此外，新的创新产品的采用，加上更容易患眼疾的老年人数量的增加，预计将在预测期内推动市场成长。

根据联合国经济和社会事务部的资料，2019年全球约有7.03亿老年人（60岁以上）。 65岁以上人口比例为6%，2019年增加至9%。从各国人口老化情况来看，2017年非洲约6,870万人，亚洲约5.492亿人，欧洲约1.83亿人，北美约7,840万人，拉丁美洲和拉丁美洲约7,840万人。万人。因此，老年人口的增加预计将推动市场。

开发中地区缺乏报销政策为寻找新的、具成本效益的分子创造了机会。此外，随着眼科医生转向更有效的新药物，公司被迫投资于研发以维持其产业地位。研究人员对现有药物的生物相似药的兴趣是抗 VEGF 治疗管道的一个主要趋势。

此外，公司正在开发各种製剂和药物传输系统，有可能增加这些治疗的采用。例如，罗氏公司（F. Hoffmann-La Roche Ltd.）开发了一种端口输送系统－RG6321（雷珠单抗），目前正在进行III期临床试验。这是一种可再填充的眼部植入，可在几个月内连续提供客製化的雷珠单抗配方。

失去专利保护可能会对市场成长产生负面影响，主要企业考虑新的收益来源。然而，生物相似药生产商的新兴市场正在形成。竞争的加剧预计将阻碍市场成长。然而，由于具有竞争优势的新产品的推出，预计预测期内限制的影响较小。

抗血管内皮生长因子疗法市场报告亮点

  • 老龄化黄斑部病变(AMD) 在 2024 年占据最大的收益占有率，预计在预测期内将保持其主导地位。
  • 2024 年，Eylea 拥有最大的产品市场占有率，达到 61.9%。 Eylea（aflibercept）是再生元製药与拜耳合作开发的抗 VEGF 治疗药物，是湿性老龄化黄斑部病变（AMD）、糖尿病黄斑部水肿（DME）和视网膜静脉曲张等视网膜疾病的一线治疗药物他已经成为一个人。
  • 北美抗血管内皮生长因子治疗市场主导全球产业，2024年占销售份额的65.71%。这是由于与老龄化的黄斑部病变（AMD）、糖尿病视网膜病变、视网膜静脉阻塞和黄斑部水肿等眼部相关疾病的盛行率不断增加。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章抗血管内皮生长因子治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 抗血管内皮生长因子治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章抗血管内皮生长因子治疗市场：依产品估计与趋势分析

  • 细分仪表板
  • 抗血管内皮生长因子治疗市场：产品波动分析
  • 抗血管内皮生长因子治疗市场：依产品分類的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 艾雷亚
  • Lucentis
  • 贝奥夫
  • 瓦维斯莫
  • 其他的

第五章抗血管内皮生长因子治疗市场：依疾病分类的估计与趋势分析

  • 细分仪表板
  • 抗血管内皮生长因子治疗市场：疾病波动分析
  • 抗血管内皮生长因子治疗市场：依疾病分类的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 黄斑部水肿
  • 糖尿病视网膜病变
  • 视网膜静脉阻塞
  • 老龄化黄斑部病变
  • 近视脉络膜新生血管

第六章抗血管内皮生长因子治疗市场：区域估计与趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 公司分类
  • 主要市场参与企业的最新趋势和影响分析
  • 2024 年企业市场占有率分析
  • 公司简介
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Pfizer, Inc.
    • Coherus BioSciences, Inc.
    • Amgen, Inc.
    • Bausch Health Companies, Inc.
    • Viatris, Inc.
Product Code: GVR-4-68038-346-1

Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth & Trends:

The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 12.90 billion by 2030, registering a CAGR of -2.35% over the forecast period, according to a new report by Grand View Research, Inc. Increased funding for R&D of anti-VEGF therapeutics to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products coupled with the increasing geriatric population that is susceptible to develop ophthalmic diseases is expected to propel the market growth over the forecast period.

According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 68.7 million in Africa, 549.2 million in Asia, 183 million in Europe, 78.4 million in North America, and more than 76 million in Latin America & other regions in 2017. Hence, the increasing geriatric population is anticipated to drive the market.

The lack of reimbursement policies in developing regions is creating an opportunity for cost-effective novel molecules. In addition, ophthalmologists switching to more effective newly launched drugs has compelled companies to invest in R&D to maintain their industry position. The interest of investigators on biosimilar of existing drugs is a major trend in the pipeline of anti-VEGF therapeutics.

Moreover, companies are developing various formulations and drug delivery systems that may increase the adoption of these therapies. For instance, F. Hoffmann La Roche Ltd. is developing the port delivery system-RG6321 (Ranibizumab)-which is currently undergoing a phase III clinical trial. It is an eye implant that is refillable and continuously delivers a customized formulation of ranibizumab over a period of months.

Loss of patent protection is likely to have a negative impact on the market growth and has led big pharma companies to consider new revenue streams. However, this is creating an emerging market for biosimilar drug producers in the space. This rising competition is anticipated to impede market growth. However, the launch of novel products with a competitive advantage is anticipated to lower the impact of the restraint during the forecast period.

Anti-vascular Endothelial Growth Factor Therapeutics Market Report Highlights:

  • In 2024, Age-related Macular Degeneration (AMD) accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
  • Eylea dominated the product segment with the largest market share of 61.9% in 2024. Eylea (aflibercept), developed by Regeneron Pharmaceuticals in collaboration with Bayer, has been a foremost anti-VEGF therapy for treating retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO
  • North America anti-vascular endothelial growth factor therapeutics market dominated the global industry and accounted for 65.71% of revenue share in 2024, which can be attributed to the increasing prevalence of eye-related conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and macular edema

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Advancements in drug delivery and development
      • 3.2.1.3. Rising awareness about early diagnosis and treatment of ocular disorders
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of anti-VEGF therapeutics
      • 3.2.2.2. Potential side effects and safety concerns
  • 3.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Movement Analysis
  • 4.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Eylea
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Lucentis
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.7. Beovu
    • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.8. Vabysmo
    • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Movement Analysis
  • 5.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Macular Edema
    • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Diabetic Retinopathy
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Retinal Vein Occlusion
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Age-related Macular Degeneration
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Myopic Choroidal Neovascularization
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company overview
    • 7.4.1. Regeneron Pharmaceuticals, Inc.
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bayer AG
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. F. Hoffmann-La Roche Ltd.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Biogen
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Pfizer, Inc.
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Coherus BioSciences, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amgen, Inc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Bausch Health Companies, Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Viatris, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 5 North America anti-vascular endothelial growth factor therapeutics, by region, 2018 - 2030 (USD Billion)
  • Table 6 North America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 7 North America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 8 U.S. anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 9 U.S. anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 10 Canada anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 12 Mexico anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 13 Mexico anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 14 Europe anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 16 Europe anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 17 UK anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 18 UK anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 19 Germany anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 20 Germany anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 21 France anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 22 France anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 23 Italy anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 24 Italy anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 25 Spain anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 26 Spain anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 27 Denmark anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 28 Denmark anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 29 Norway anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 30 Norway anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 31 Sweden anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 32 Sweden anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 36 Japan anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 37 Japan anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 38 China anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 39 China anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 40 India anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 41 India anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 42 Australia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 43 Australia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 44 South Korea anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 45 South Korea anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 46 Thailand anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 47 Thailand anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 48 Latin America anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 50 Latin America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 51 Brazil anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 52 Brazil anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 53 Argentina anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 54 Argentina anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 55 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 56 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 58 South Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 59 South Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 62 UAE anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 63 UAE anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Anti-vascular endothelial growth factor therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and disease segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market value, 2024 (USD Billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Prevalence of diabetic retinopathy in the U.S. in 2021
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Anti-vascular endothelial growth factor therapeutics market: Product outlook and key takeaways
  • Fig. 17 Anti-vascular endothelial growth factor therapeutics market: Product movement analysis
  • Fig. 18 Eylea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lucentis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Beovu market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Vabysmo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Anti-vascular endothelial growth factor therapeutics market: Disease outlook and key takeaways
  • Fig. 24 Anti-vascular endothelial growth factor therapeutics market: Disease movement analysis
  • Fig. 25 Macular edema market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetic retinopathy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Retinal vein occlusion market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Age-related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Myopic choroidal neovascularization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-vascular endothelial growth factor therapeutics market revenue, by region, 2024 & 2030 USD Million
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Prevalence of Diabetic Retinopathy (DR) in 2021, in U.S., in Million
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Mexico anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Germany anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 France anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Spain anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Sweden anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Norway anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Japan anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 China anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 India anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Australia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Thailand anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Brazil anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Argentina anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamic
  • Fig. 87 Kuwait anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Rest of MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Company/competition categorization
  • Fig. 90 Company market share analysis, 2024
  • Fig. 91 Strategy mapping